Results 81 to 90 of about 2,468 (182)

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Journal of the American College of Cardiology, 2016
Idarucizumab is a specific reversal agent that rapidly neutralizes dabigatran’s anticoagulant activity [(1–3)][1]. We investigated restoration of dabigatran anticoagulation 24 h after idarucizumab treatment and the safety and effectiveness of a second idarucizumab treatment.
Stephan, Glund, Joachim, Stangier, Joanne, van Ryn, Michael, Schmohl, Viktoria, Moschetti, Wouter, Haazen, Marina, De Smet, Dietmar, Gansser, Stephen, Norris, Benjamin, Lang, Paul, Reilly, Jörg, Kreuzer   +11 more
openaire   +2 more sources

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Sonorheometry parameters during dabigatran reversal with idarucizumab for major bleeding

International audienceBleeding during oral anticoagulant therapy is currently codified by expert guidelines. Monitoring coagulation during bleeding events remains challenging.
Lebreton, Aurélien, Teissandier, Dorian, Rousseau, Geoffroy, Pereira, Bruno, Lucchini, Camille, Teulade, Boris, Joly, Camille, Schmidt, Jeannot, Moustafa, Farès   +8 more
core   +1 more source

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran

Vascular Health and Risk Management, 2019
David Giannandrea,1,2,* Anna Mengoni,3,* Erberto Carluccio,3 Giuseppe Ambrosio31Neurology Departement - Stroke Unit, Gubbio/Gualdo Tadino Hospitals, Perugia, Italy; 2Association “Naso Sano”, Umbria Regional Registry of No-Profit Organization,
Giannandrea D, Mengoni A, Carluccio E, Ambrosio G   +3 more
doaj  

Modern strategy of antithrombotic therapy in patients with coronary artery disease and atrial fibrillation after percutaneous coronary intervention

Российский кардиологический журнал, 2019
Reducing of cardiovascular risk, morbidity and mortality is considered as one of the main aims of modern cardiology, which should help increase life expectancy.
Yu. A. Karpov
doaj   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Idarucizumab for Dabigatran Reversal in Clinical Practice: A French Retrospective Studyof 41 Cases

, 2019
International audienceBackground : Idarucizumab is a specific antidote for dabigatranreversal. Since his approval, clinical experience with its use is stilllimited. We previsouly demonstrated that initial dabigatran plasmalevel above 200ng/ml predicted a
Lasne, Dominique
core   +1 more source

Utilizzo di Idarucizumab [PDF]

, 2019
Utilizzo in Toscana di idarucizumab, antidoto di ...
Lombardi Niccolò, Crescioli Giada, Bettiol Alessandra, Vannacci Alfredo, Brilli Valentina, Mannaioni Guido, Fumagalli Stefano, Gini Rosa, Mazzaglia Giampiero   +8 more
openaire  

A eficácia e segurança do idarucizumab na reversão do efeito anticoagulante do dabigatrano

, 2017
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2017O dabigatrano etexilato pertence à classe dos novos anticoagulantes orais, que segundo as mais recentes diretrizes deverão ser a opção de ...
Caetano, Catarina de Mendonça Machado Afonso
core   +3 more sources

Farmacocinética de dabigatrán y utilización de su antídoto idarucizumab

, 2022
Resumen Una de las ventajas de dabigatrán, un nuevo anticoagulante oral de acción directa, es la disponibilidad de un antídoto que permite revertir su actividad: idarucizumab.
Delgado-Téllez-de Cepeda,L, Hernández-Terciado,C, Sánchez-Guerrero,A, De Santiago-Álvarez,R   +3 more
core   +1 more source